Get the Daily Brief
Latest Biotech News
Mechanisms meet therapeutics: NEK7 biology and CAR-macrophages attack liver fibrosis
Two independent preclinical advances target liver fibrosis from complementary angles. A CAR‑macrophage therapy reduced fibrosis in mouse models, demonstrating that engineered macrophages can be...
Next‑gen oncology inhibitors: PRMT5 and TEAD programs show preclinical traction
Tango Therapeutics reported preclinical efficacy for TNG‑456, a selective, MTA‑cooperative PRMT5 inhibitor showing antitumor activity in glioma and metastasis-prone tumors. The compound targets...
WGS from FFPE: method unlocks archival tumor genomes
Researchers developed a robust workflow enabling whole-genome sequencing (WGS) from formalin-fixed paraffin-embedded (FFPE) tissue specimens, overcoming historical limitations of DNA damage and...
Aspen raises $115m Series C: scales iPSC Parkinson’s program
Aspen Neuroscience closed a $115 million Series C to accelerate clinical development of ANPD001 and expand manufacturing for autologous iPSC‑derived therapies. The company said proceeds will...
Vigencell’s lymphoma cell therapy meets phase II endpoint – regulatory move planned
Vigencell reported positive top‑line results from a Phase II study of VT‑EBV‑N, an antigen‑specific killer T‑cell therapy targeting NK/T‑cell lymphoma, and plans to seek conditional approval in...
CSPC cleared to start JMT‑206 obesity trials in China – NMPA gives green light
CSPC Pharmaceutical Group received clinical trial clearance from China’s National Medical Products Administration (NMPA) to test JMT‑206 for weight management in people with obesity or overweight...
Novo files high‑dose Wegovy with FDA – voucher to expedite review
Novo Nordisk submitted a higher‑dose formulation of Wegovy to the U.S. Food and Drug Administration, using an awarded voucher to speed the review timetable. The filing aims to broaden dosing...
Drug pricing shakeup: CMS cuts and MFN guidance reshape GLP‑1 economics
Two policy moves crystallized pricing pressure on high‑revenue drugs. CMS published negotiated prices under the Inflation Reduction Act that industry analysts say translate into larger net...
SK Biopharma in‑licenses WT‑7695: radiopharmaceutical rights inked
SK Biopharmaceuticals struck an exclusive worldwide license with the Wisconsin Alumni Research Foundation (WARF) to develop, manufacture and commercialize WT‑7695, a preclinical...
WGS from FFPE: robust method unlocks archival tumor genomes
Researchers published a validated workflow enabling robust whole‑genome sequencing (WGS) from formalin‑fixed, paraffin‑embedded (FFPE) tumor specimens, overcoming longstanding technical hurdles....
Allogeneic iPSC‑iNKT cells tested in head and neck cancer – early clinical signals
Investigators reported initial clinical testing of allogeneic induced pluripotent stem cell (iPSC)‑derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer. The Phase I...
CrisprBits lands $3m pre‑Series A – expands CRISPR diagnostics and R&D
Indian biotech CrisprBits closed a US$3 million pre‑Series A round led by Spectrum Impact, the family office of Rajendra Gogri, to expand CRISPR‑based diagnostics and R&D capabilities. The funding...
FDA’s ‘plausible mechanism pathway’: experts split on bespoke rare‑disease route
FDA officials Vinay Prasad and Martin Makary published a ‘plausible mechanism pathway’ proposing expedited approval routes for bespoke medicines in rare diseases, drawing praise and criticism from...
Aspen raises $115m – scales autologous Parkinson’s iPSC program
Aspen Neuroscience announced a $115 million Series C to accelerate clinical development and manufacturing scale-up for ANPD001, its autologous iPSC-derived cell therapy for Parkinson’s disease....
CSPC cleared to test JMT‑206 in China: obesity clinic entry granted
China’s NMPA granted clinical trial clearance for CSPC Pharmaceutical Group’s JMT‑206, a candidate for weight management in people with obesity or overweight plus comorbidity. CSPC will start...
Novo files high‑dose Wegovy – voucher expedites FDA review
Novo Nordisk submitted a higher‑dose formulation of its obesity drug Wegovy to the FDA and is using a regulatory voucher to accelerate review. The company seeks approval to expand dosing options...
CMS posts second drug‑price list… biopharma braces for deeper cuts
The U.S. Centers for Medicare & Medicaid Services released its second list of negotiated drug prices under the Inflation Reduction Act, laying out adjusted maximum fair prices for 15 medicines and...
Cell therapy momentum... iPSC‑iNKT and VT‑EBV‑N hit clinical milestones
Two cell‑therapy programs reported meaningful clinical progress this week. A phase 1 trial of allogeneic iPSC‑derived invariant natural killer T (iNKT) cells demonstrated early safety signals and...
SK Biopharma inks WARF license for WT‑7695 radiopharmaceutical
SK Biopharmaceuticals signed an exclusive worldwide license with the Wisconsin Alumni Research Foundation (WARF) for WT‑7695, a preclinical radiopharmaceutical developed with the University of...
Drug‑degradation race: Blueprint patents CDK4 PROTACs; Gluetacs shows molecular glues
Blueprint Medicines disclosed new PROTAC compounds targeting CDK4, claiming proteolysis‑based degradation as a route to overcome resistance to classical kinase inhibitors. Separately, Gluetacs...